MDNews - Lower Hudson/Bronx

January 2017

Issue link: https://viewer.e-digitaledition.com/i/773802

Contents of this Issue

Navigation

Page 16 of 23

insults such as high blood glucose levels, says James Kirkland, MD, PhD, Director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic and senior author of the research study. "These cells have been noted to accu- mulate a round tissues in histologica l sections of joints from people who've had osteoa r thritis a nd have a knee or hip replacement ...," Dr. Kirkland says. " Whether they are a cause or an e¥ ect or an incidenta l fi nding with respect to osteoarthritis hasn't been shown before. What we set out to do was show whether senescent cells in a nd of themselves could promote or cause the development of an osteoarthritis-like state. If so, that would argue that they contribute to the etiology and be one of the things that ties predisposition to osteoa r thritis with chronologica l aging." INVESTIGATIONAL HIGHLIGHTS To explore the potential causal relation- ship between senescent cells a nd OA development, the research team injected 100,000 senescent or nonsenescent cells into and around the knee joints of mice, which ra rely develop age-related OA . Cells used in the study were fi broblasts harvested from each animal's ear carti- lage. To induce cellular senescence, the cells were placed into culture and treated with either radiation or a chemotherapy drug. Seven mice received injections of senescent cells, and seven received injections of nonsenescent cells that were grown para llel in culture. M ic e t h a t r e c eive d i nje c t ion s of senescent cells developed many of the ha llmarks of OA, including pain in the knee joint and decreased joint function- ality. Narrowing of the joint space, loss of bone near the knee joint and bony spurs were also observed on X-ray. The animals that received injections of nonsenescent cells exhibited no signifi cant OA-related changes. In addition, pathologic changes associated with OA were obser ved in histologica l samples ta ken from mice that received the senescent cell injection. A NEW APPROACH TO OA? T he s t udy 's resu lt s revea l t h at t he accumulation of senescent cells in joints is indeed causa l for OA , according to Dr. Kirkla nd. Based on these results, treating OA with drugs that target senes- cent cells may help slow progression of the disease, a condition for which there are no approved disease-modifying drugs. Senolytic drugs — a new class of phar- maceutical agents that were developed in 2015 a nd help destroy a nd remove senescent cells — may hold the key to treating age-related OA. Moving forward, research that tests whether or not seno- ly tic drugs help prevent, delay or treat OA in a nima l models is necessa r y. If animal trials are positive, clinical trials in humans will likely follow, according to Dr. Kirkland. Current OA treatment strategies are not curative. They include weight loss, physical therapy, and the use of nonste- roidal anti-infl ammatory medications, corticosteroid injections, braces and/or assistive devices. In cases of end-stage, or bone-on-bone, OA, joint replacement surgery may be recommended. Due to advances in surgical technique and implant technology, joint replacement is a safe and long-lasting solution for hip and knee OA. However, joint replacement surgery is often used more discriminately and may not be as e¥ ective in treating OA in other joints, such as the ankle. Ankle implants, for example, usually last only 10 years in ideal scenarios. Disease- modifying, senolytic agents may be an important complement for OA treatment, especially in joints that may not respond as well to surgery. "We have excellent surgical treatment strategies that are very successful and relieve pain, improve function, and get people back to work and back to their lives ...," Dr. Lajam says. "However, there's always room for improvement, and we're continuing as orthopedic surgeons to look for those. ... We hope in the future that we will have some even better solutions." ■ " There is a whole lot we don't know about the development and progression of osteoarthritis. These studies ... that look at the causal factors will allow us to develop disease-modifying agents in the future [that] will be really life-altering for millions of people. There's a lot of research to be done that could potentially have a great impact on the disease." A. HOLLY JOHNSON, MD, INSTRUCTOR IN ORTHOPEDIC SURGERY AT HARVARD MEDICAL SCHOOL, FOOT AND ANKLE SURGEON AT MASSACHUSETTS GENERAL HOSPITAL SPECIAL CLINICAL SECTION: ORTHOPEDICS 1 7 M D N E W S .C O M /// M D N E W S L O W E R H U D S O N / B R O N X ■ 2 017

Articles in this issue

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - January 2017